Amgen Inc. (AMGN)
Amgen Stock: New All-Time Highs Ahead After Earnings Beat
Amgen Inc. NASDAQ: AMGN just delivered a strong beat-and-raise quarter. That's pushed the stock to within striking distance of its 52-week high.
Amgen's Q3 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up
AMGN's Q3 earnings and revenues top estimates as key drugs drive double-digit growth. The company also raises its 2025 outlook.
Amgen (AMGN) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Amgen (AMGN) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Amgen (AMGN) Q3 Earnings and Revenues Beat Estimates
Amgen (AMGN) came out with quarterly earnings of $5.64 per share, beating the Zacks Consensus Estimate of $5 per share. This compares to earnings of $5.58 per share a year ago.
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know
Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Amgen (AMGN) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
Get a deeper insight into the potential performance of Amgen (AMGN) for the quarter ended September 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Amgen's Q3 Earnings in the Cards: Here's What to Expect
Amgen's Q3 results are on deck, with growth from newer drugs offset by biosimilar competition and pricing pressures.
Earnings Preview: Amgen (AMGN) Q3 Earnings Expected to Decline
Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amgen (AMGN) Laps the Stock Market: Here's Why
In the closing of the recent trading day, Amgen (AMGN) stood at $297.32, denoting a +1.18% move from the preceding trading day.
Why Amgen (AMGN) Could Beat Earnings Estimates Again
Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Amgen (AMGN) Stock Sinks As Market Gains: Here's Why
Amgen (AMGN) reached $294.12 at the closing of the latest trading day, reflecting a -1.27% change compared to its last close.
Amgen Lowers Cholesterol-Medication Price After Trump Call for Price Cuts
The biotechnology company said that it has launched AmgenNow, a new direct-to-patient program, starting with its drug Repatha.
